Earnings Releases·Oct 28, 2026, 4:10 PM ET

Glaukos Corporation — Third Quarter 2026 Earnings Summary

Net sales reached a record $211.0 million in Q3 2026, a 58% year-over-year increase, while GAAP net income turned positive at $2.0 million compared to a $16.2 million loss in the prior year period.
Raised 2026 net sales guidance to $775–$785 million from $680–$700 million and introduced preliminary 2027 guidance of $1 billion, driven by growth in the U.S. Glaucoma (47% YoY) and Corneal Health (154% YoY) segments.
Achieved non-GAAP net income of $28.5 million and a non-GAAP gross margin of 88%, supported by $339.8 million in cash and zero debt as of September 30, 2026.
Recorded $20.0 million in one-time expenses related to litigation and a resolution agreement with the Regents of the University of California, while SG&A expenses increased 58% to $130.9 million.